Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker7Thank you for standing by, and welcome to Ligand's fourth quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by 1 on your telephone keypad. If you would like to withdraw your question, please press star one again. ...

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. As previously disclosed in Biofrontera’s filings ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites in the U.S., U.K. ...

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is recognized as one of the best investment stocks for 2026, indicating strong future potential in the market [1][2]. Company Developments - Truist Securities downgraded HRMY from Buy to Hold due to concerns raised during a patent trial against AET Pharma, suggesting a potential negative outcome for Harmony's case and highlighting risks for the Wakix franchise, with generic competition expected before 2029 [3][8]. - On February 17, the U.S. FDA approved Harmony's supplemental New Drug Application for WAKIX (pitolisant) tablets, allowing treatment for cataplexy in children aged six and older, marking it as the first FDA-approved non-scheduled therapy for narcolepsy [4][5]. Industry Context - Harmony Biosciences focuses on developing therapies for rare neurological disorders, particularly innovative treatments for narcolepsy and other sleep-related diseases, positioning itself within a niche but critical segment of the biopharmaceutical industry [5].

Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on APLS: Dis ...

Core Insights - Disc Medicine, Inc. reported financial results for Q4 and full year 2025, highlighting progress in its clinical programs and a strong cash position [1][5][6] Financial Performance - Cash, cash equivalents, and marketable securities totaled approximately $791 million as of December 31, 2025, up from $490 million in 2024, providing a runway into 2029 [6][11] - Research and Development (R&D) expenses increased to $170.6 million in 2025 from $96.7 million in 2024, driven by advancements in clinical studies and increased headcount [11][13] - Selling, General and Administrative (SG&A) expenses rose to $65.4 million in 2025 from $33.0 million in 2024, primarily due to increased headcount and infrastructure development [11][13] - The net loss for 2025 was $212.2 million, compared to a net loss of $109.4 million in 2024, attributed to higher operating costs [11][13] Clinical Developments - The Phase 3 APOLLO study for bitopertin is expected to complete enrollment in March 2026, with topline data anticipated in Q4 2026 [6][7] - Initial data from the Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) showed meaningful overall anemia responses across all patient subgroups [6][7] - The company is progressing with the Phase 2 study of DISC-3405 in polycythemia vera and has initiated a Phase 1b study in sickle cell disease, with data expected in the second half of 2026 [6][7] Pipeline Overview - Bitopertin is a GlyT1 inhibitor aimed at treating erythropoietic protoporphyria (EPP) [3] - DISC-0974 is an anti-hemojuvelin antibody focused on hepcidin suppression [4] - DISC-3405 is an anti-TMPRSS6 antibody targeting hepcidin induction [4]

THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at http ...

Fourth Quarter and Full Year 2025 Financial Results F E B R U A R Y 2 6 , 2 0 2 6 | FINANCIAL | 48% Full-year royalty revenue growth over 2024 | | --- | --- | | Strong financial performance | 42% Full-year core adjusted EPS growth to $8.131 per share | | BUSINESS DEVELOPMENT | Scaling the BD function to capture value from our deep investment pipeline | | Highly productive, rigorous process | ~$1B Deployable capital (including credit facility) | | | Positions us for continued growth and expansion across our ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) , a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system (CNS) disorders, specifically suicidal bipolar depression, chronic pain and PTSD, is making further inroads on that front. The company just announced it completed an in-person meeting with the U.S. Food and Drug Administration (FDA) over NRX-100, its developmental drug for treating suicidal depression. NRX-100 is a preservative-fr ...

Core Viewpoint - Pulmatrix, Inc. is focusing on advancing its proposed merger with Cullgen while also seeking to license or monetize its iSPERSE™ technology and related clinical programs, particularly in the context of its financial results for the year-end and fourth quarter of 2025 [1][2]. Financial Performance - Revenues for the year ended December 31, 2025, decreased to $0 from $7.8 million in 2024, primarily due to the wind down of the PUR1900 program [2]. - Research and development expenses dropped to less than $0.1 million in 2025 from $7.2 million in 2024, attributed to the cessation of the PUR1900 Phase 2b clinical trial and related operational reductions [2]. - General and administrative expenses decreased to $5.1 million in 2025 from $7.8 million in 2024, reflecting lower employment and operational costs [2]. - The total cash and cash equivalents as of December 31, 2025, were $4.1 million, down from $9.5 million in 2024, with expectations to fund operations into the first quarter of 2027 [2]. Proposed Merger with Cullgen - Pulmatrix entered into a merger agreement with Cullgen on November 13, 2024, with subsequent amendments, and is currently awaiting approval from the China Securities Regulatory Commission (CSRC) [1]. - The merger agreement includes a waiver of the "No Solicitation" clause, allowing both companies to explore alternative transactions while pursuing merger approval [1][2]. iSPERSE™ Technology and Clinical Programs - Pulmatrix's iSPERSE™ technology includes approximately 149 granted patents and 48 pending applications, aimed at improving drug delivery for respiratory diseases [1]. - The company is advancing its clinical programs, including PUR3100, which is ready for Phase 2 trials for acute migraine treatment, and PUR1800, which is being developed for chronic obstructive pulmonary disease [1][2]. - PUR1900, an inhaled formulation of itraconazole, is in Phase 3 trials in India, with Pulmatrix receiving 2% royalties on future net sales outside the U.S. [1][2].